2010 Venture Capital Oscar Predictions

Even though Oscar buzz is not yet in the air, it is pretty clear what film titles will rule in 2010. So sit back, grab your popcorn…the envelopes please.

Precious: The statuette goes to this film about the Greenback, which continues to be really hard to come by. The venture industry weathered a swift-yet-painful contraction in 2009, which shows little sign of letting up. In 2008, the U.S. venture capital industry raised nearly $30 billion; although the 2009 data are yet to be compiled, it appears that last year the industry will have raised less than $15 billion—which may be the new annual reality. For entrepreneurs, this contraction will continue to make capital precious and hard to access.

New England-based companies raised nearly $3 billion in 2008; my guess is that this number will look closer to $2 billion in 2009. The New England Venture Capital Association, which I currently chair, had 138 dues-paying members two years ago; right now, we have 108 members. Fortunately for New England, more than 20 percent of all venture capital is managed by firms based in Massachusetts.

It’s Complicated: The star of this film: the local business environment, which will continue to be tricky to navigate. While there is abundant innovation and a number of high-quality entrepreneurs in the market, it is hard to handicap which compelling and profitable investment themes will emerge. Last year investors thought 2009 was going to be the “year of cleantech,” but instead of (global) warming, that investment theme seemed to have cooled. I continue to see great opportunities in the convergence of the IT and life sciences sectors, which New England is uniquely positioned to exploit. There are also wonderful opportunities in cloud computing and with new advertising technologies, but all of this is complicated by the absolute dearth of liquidity.

2012: And the Academy is pleased to recognize this blockbuster, which unfortunately may portend that the real economic recovery is still a few years away. All of us are desperate for predictable, sustainable, and meaningful liquidity. Many of our portfolio companies are at a point of maturity, where in more normal times they would either go public or be sold at attractive M&A prices. Average holding periods have extended to more than eight years, which is unprecedented; normally VC’s expect this to be between four and six years. There will be around a dozen venture-backed IPOs in 2009; this would be closer to 100 in more normal years.

And honorable mentions go to….

In the Air: This flick recognizes that all of us will have to work much harder this upcoming year just to stay in place!

Blind Side: Although this title better describes how we all felt (blind-sided, to be more exact) in the fall of 2008, we should expect that there well may be additional economic shocks as we collectively crawl out of this turmoil.



Author: Michael A. Greeley

Michael is a General Partner at Flare Capital Partners. Prior to co-founding Flare Capital Partners, Michael was the founding General Partner of Flybridge Capital Partners where he led the firm’s healthcare investments. Current and prior board seats include BlueTarp Financial, Circulation, EndoGastric Solutions, Explorys, Functional Neuromodulation, HealthVerity, Iora Health, MicroCHIPS, Nuvesse, PolyRemedy, Predictive Biosciences, Predilytics, T2 Biosystems, TARIS Biomedical, VidSys and Welltok. Previously, Michael focused on emerging-growth company financings with Polaris Venture Partners, was a senior vice president and founding partner of GCC Investments, and held positions at Wasserstein Perella & Co., Morgan Stanley & Co. and Credit Suisse First Boston. Michael currently serves as chairman of the Entrepreneurship Committee of the Massachusetts Information Collaborative and on the Investment Committee for the Partners Innovation Fund and Massachusetts Eye & Ear Infirmary. Michael also serves on the Industry Advisory Board of the Cleveland Clinic and Boston Children’s Hospital, as well as serving on several other boards including the New England Investors’ Committee of Capital Innovation. He was the former chairman of the New England Venture Capital Association and on the Executive Committee of the board of the National Venture Capital Association. Named by the Boston Globe as the “Go-To” investor for life sciences, healthcare and medical devices and a Mass High Tech All-Star, Michael earned a B.A. with honors in chemistry from Williams College and an M.B.A. from Harvard Business School. Michael authors a blog focused on venture capital, innovation and healthcare at www.ontheflyingbridge.com.